Oral drug Roxadustat safe and effective for anemia treatment in kidney disease patients: Study

Written By : Hina Zahid

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2021-08-11 03:30 GMT | Update On 2021-08-11 10:01 GMT

Roxadustat was shown to be effective, with an acceptable safety profile. USA: An oral drug called roxadustat is effective for the treatment of anemia in patients with chronic kidney disease, shows pooled results from recent clinical trials. The study results appear in the Clinical Journal of the American Society of Nephrology (CJASN).

Many people with kidney dysfunction develop anemia -- a shortage of healthy red blood cells that carry oxygen to the body's tissues. Some anemia treatments may lead to serious cardiovascular side effects.

A new class of oral drugs called hypoxia inducible factor-prolyl hydroxylase inhibitors may be comparable to placebo in these trials. These drugs act on the pathway involved in the production of erythropoietin that stimulates red blood cell formation.

To evaluate the efficacy and cardiovascular safety of one such inhibitor -- called roxadustat -- Robert Provenzano, MD (Wayne State University School of Medicine) and his colleagues analyzed data pooled from three phase 3 studies of roxadustat in patients with chronic kidney disease and anemia.

In total, 2,391 patients received roxadustat and 1,886 received a placebo. Roxadustat treatment boosted levels of hemoglobin (the protein in red blood cells responsible for transporting oxygen): roxadustat- vs. placebo-treated patients showed an average change in hemoglobin averaged over weeks 28 to 52 of 1.9 vs. 0.1 g/dL. Roxadustat also reduced the need for red blood cell transfusions in the first 52 weeks, and there were no increased risks of mortality, heart attacks, strokes linked to the drug.

"Roxadustat was shown to be effective, with an acceptable safety profile," said Dr. Provenzano. "As an oral agent, roxadustat addresses the significant unmet need in treating anemia in patients with kidney disease."

Reference:

The study titled, "Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non–Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials," is published in the journal CJASN.

DOI: https://cjasn.asnjournals.org/content/16/8/1190

Article Source : Clinical Journal of the American Society of Nephrology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Hina Zahid

Hina Zahid Joined Medical Dialogue in 2017 with a passion to work as a Reporter. She coordinates with various national and international journals and association and covers all the stories related to Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in the medical field. Email: editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Oral drug Roxadustat safe and effective for anemia treatment in kidney disease patients: Study

Similar News

Pediatric Pain Relief: The Role of Regional Anesthesia in Renal Disease Management, study finds

Dual Imaging Approach Enhances Early Detection of Contrast-Induced Nephropathy in Animal Model: Experimental Study

Poor Heart-Kidney-Metabolic Health and Genetics May Double Psoriasis Risk, Study Finds

Thirst Distress Common and Overlooked in Hemodialysis Patients: Study Suggests

Low-intensity extracorporeal shock wave therapy ineffective for Post-Prostatectomy Erectile Dysfunction: Study

Ureteroscopy and Shockwave Lithotripsy exhibit Similar kidney stone Clearance: JAMA

HCQ Shows Promise in Reducing Proteinuria in Primary Glomerular Diseases: Study

Neutrophil-to-lymphocyte ratio Linked to Poor Outcomes in CKD and MACE: Study